Stemline Therapeutics, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open Stemline Therapeutics, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ELCIN NCT05596409 |
P2 | Active, not recruiting | Metastatic Breast Cancer | 61 | 2026-11 (+27 mo) |
| ELECTRA NCT05386108 |
P1/2 | Recruiting | Breast Neoplasms; Brain Neoplasms | 73 | 2026-12 (+12 mo) |
| ELEVATE NCT05563220 |
P1/2 | Active, not recruiting | Breast Cancer; Metastatic Breast Cancer | 435 | 2026-12-27 (+24 mo) |
| TRILLIUM NCT06456463 |
P2 | Active, not recruiting | Acute Myeloid Leukemia | 85 | 2028-02-09 |
| MEN2312 NCT07873827 |
P1/2 | Not yet recruiting | Hematological Malignancy | 115 | 2028-05-12 |
| Elacestrant NCT07766018 |
P2 | Recruiting | Breast Cancer | 70 | 2028-10 |
| ELEGANT NCT06492616 |
P3 | Active, not recruiting | Breast Cancer | 4556 | 2029-08 |